The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms - PubMed (original) (raw)

. 2014 Dec;171(6):1585-8.

doi: 10.1111/bjd.13162. Epub 2014 Oct 27.

Affiliations

• PMID: 24903194
• DOI: 10.1111/bjd.13162

The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms

H Fujita et al. Br J Dermatol. 2014 Dec.

No abstract available

PubMed Disclaimer

Similar articles

• Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.
  Inoue Y, Saito T, Tsuruoka Y, Sato K, Nishio Y, Suzuki Y, Kato M, Isobe Y, Sakai H, Takahashi M, Miura I. Inoue Y, et al. Thromb Res. 2013 Oct;132(4):493-4. doi: 10.1016/j.thromres.2013.08.020. Epub 2013 Sep 1. Thromb Res. 2013. PMID: 24050827 No abstract available.
• High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome.
  Nakajima S, Watanabe H, Tohyama M, Sugita K, Iijima M, Hashimoto K, Tokura Y, Nishimura Y, Doi H, Tanioka M, Miyachi Y, Kabashima K. Nakajima S, et al. Arch Dermatol. 2011 Sep;147(9):1110-2. doi: 10.1001/archdermatol.2011.239. Arch Dermatol. 2011. PMID: 21931056 No abstract available.
• Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions.
  Mori S, Hickey A, Dusza SW, Lacouture ME, Markova A. Mori S, et al. J Am Acad Dermatol. 2019 Mar;80(3):608-616. doi: 10.1016/j.jaad.2018.10.039. Epub 2018 Oct 26. J Am Acad Dermatol. 2019. PMID: 30612984 Free PMC article.
• HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis.
  de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. de Souza AW, et al. Autoimmun Rev. 2012 Oct;11(12):909-17. doi: 10.1016/j.autrev.2012.03.007. Epub 2012 Apr 1. Autoimmun Rev. 2012. PMID: 22495229 Review.
• [CME. Severe cutaneous drug reaction].
  Deuel J, Schaer D, Schmid-Grendelmeier P, Vallelian F. Deuel J, et al. Praxis (Bern 1994). 2014 Oct 15;103(21):1231-43. doi: 10.1024/1661-8157/a001809. Praxis (Bern 1994). 2014. PMID: 25305114 Review. German. No abstract available.

Cited by

• Role of Multiple Comorbidities and Therapies in Conditioning the Clinical Severity of DRESS: A Mono-Center Retrospective Study of 25 Cases.
  Toniato A, Gamba C, Schroeder JW, Fabbri V, Bernal Ortiz SV, Borgonovo L, Piantanida M, Scibilia J, Balossi L, Brusamolino E, Bonoldi E, Caputo V, Nichelatti M, Pastorello EA. Toniato A, et al. Int J Mol Sci. 2021 Jun 30;22(13):7072. doi: 10.3390/ijms22137072. Int J Mol Sci. 2021. PMID: 34209467 Free PMC article.
• Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
  Cheng L. Cheng L. Front Pharmacol. 2021 Apr 26;12:588063. doi: 10.3389/fphar.2021.588063. eCollection 2021. Front Pharmacol. 2021. PMID: 33981213 Free PMC article. Review.
• Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.
  Bellón T. Bellón T. Drug Saf. 2019 Aug;42(8):973-992. doi: 10.1007/s40264-019-00825-2. Drug Saf. 2019. PMID: 31020549 Review.
• Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
  Carr DF, Wang CW, Bellón T, Ressel L, Nwikue G, Shrivastava V, Bergfeld W, Jorgensen AL, Chung WH, Pirmohamed M. Carr DF, et al. Br J Dermatol. 2019 Jul;181(1):166-174. doi: 10.1111/bjd.17610. Epub 2019 Mar 26. Br J Dermatol. 2019. PMID: 30613954 Free PMC article.
• Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.
  Watanabe H. Watanabe H. J Immunol Res. 2018 Mar 18;2018:5163129. doi: 10.1155/2018/5163129. eCollection 2018. J Immunol Res. 2018. PMID: 29744372 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems
  • Wiley

• Other Literature Sources

  • scite Smart Citations